Krajina: Írsko
Jazyk: angličtina
Zdroj: HPRA (Health Products Regulatory Authority)
APRACLONIDINE HYDROCHLORIDE
Alcon Laboratories (UK) Ltd
S01EA03
APRACLONIDINE HYDROCHLORIDE
5 Mg/Ml
Eye Drops Solution
Product subject to prescription which may be renewed (B)
Sympathomimetics in glaucoma therapy
Authorised
1995-04-21
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Iopidine 5 mg/ml Eye Drops, Solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml of solution contains Apraclonidine 5 mg (as hydrochloride). Excipients: 1 ml of solution contains 0.1 mg benzalkonium chloride For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Eye drops, solution A colourless to pale yellow solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS IOPIDINE 5mg/ml is indicated for short-term adjunctive therapy of chronic glaucoma in patients on maximally tolerated medical therapy who require additional intraocular pressure (IOP) reduction to delay laser treatment or glaucoma surgery. The IOP lowering efficacy of IOPIDINE diminishes over time in most patients. Although some patients have received successful treatment with IOPIDINE for longer periods, the benefit for most patients is less than one month. The addition of IOPIDINE to patients already using two aqueous suppressing drugs (i.e. beta-blockers plus carbonic anhydrase inhibitor) as part of their maximally tolerated medical therapy may not provide additional benefit. This is because IOPIDINE is an aqueous suppressing drug and the addition of a third aqueous suppressant may not significantly reduce IOP. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION One drop of IOPIDINE should be instilled into the affected eye(s) three times per day (t.i.d.). Since IOPIDINE will be used with other ocular glaucoma therapies, an approximate five minute interval between instillation of each medication should be observed to prevent washout of the previous dose. If, for any reason, the drop of IOPIDINE does not remain in the eye, then the patient should repeat the dose by placing another drop in the eye. The maximum recommended duration of therapy is Prečítajte si celý dokument